Literature DB >> 20661049

Stillbirth: fetal disorders.

Richard M Pauli1.   

Abstract

Fetal disorders (including congenital malformations) are among the most frequent of causes of intrauterine death. Assessment to detect fetal processes is straightforward: history (prenatal, perinatal, and family); external clinical examination; photographs; whole body radiographs; cytogenetic investigation; and internal necropsy. Unfortunately such investigations are profoundly underused. When appropriately and nonselectively assessed, about one-fifth of all stillborn infants will be found to have a fetal cause of their death. Fetal diagnoses are markedly heterogeneous, with no single process accounting for more than 1.5% of all fetal deaths. Identifying a fetal cause has marked implications for the family and changes some elements of counseling and care in more than half of those whose stillborn infants were adequately evaluated. Currently unmet needs include research needs including efforts to understand the variability of intrauterine effects of fetal disorders and their causes, and clinical needs, particularly related to funding for evaluation of stillborns and development of geographically dispersed multidisciplinary commitment and expertise devoted to stillbirth evaluation.

Entities:  

Mesh:

Year:  2010        PMID: 20661049     DOI: 10.1097/GRF.0b013e3181eb6755

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  2 in total

1.  Routine perinatal and paediatric post-mortem radiography: detection rates and implications for practice.

Authors:  Owen J Arthurs; Alistair D Calder; Liina Kiho; Andrew M Taylor; Neil J Sebire
Journal:  Pediatr Radiol       Date:  2013-11-08

2.  Proposing a machine-learning based method to predict stillbirth before and during delivery and ranking the features: nationwide retrospective cross-sectional study.

Authors:  Toktam Khatibi; Elham Hanifi; Mohammad Mehdi Sepehri; Leila Allahqoli
Journal:  BMC Pregnancy Childbirth       Date:  2021-03-12       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.